Cargando…

A comprehensive analysis of Fanconi anemia genes in Chinese patients with high-risk hereditary breast cancer

BACKGROUND: Four Fanconi anemia (FA) genes (BRCA1, BRCA2, PALB2 and RAD51C) are defined as breast cancer (BC) susceptibility genes. Other FA genes have been inconsistently associated with BC. Thus, the role of other FA genes in BC should be explored in specific populations. METHODS: Mutations in 16...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Qiao-Yan, Li, Pu-Chun, Zhu, Yi-Fan, Pan, Jia-Ni, Wang, Rong, Li, Xiao-Lin, Ye, Wei-Wu, Ding, Xiao-Wen, Wang, Xiao-Jia, Cao, Wen-Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590287/
https://www.ncbi.nlm.nih.gov/pubmed/37566130
http://dx.doi.org/10.1007/s00432-023-05236-6
_version_ 1785123958945742848
author Zhu, Qiao-Yan
Li, Pu-Chun
Zhu, Yi-Fan
Pan, Jia-Ni
Wang, Rong
Li, Xiao-Lin
Ye, Wei-Wu
Ding, Xiao-Wen
Wang, Xiao-Jia
Cao, Wen-Ming
author_facet Zhu, Qiao-Yan
Li, Pu-Chun
Zhu, Yi-Fan
Pan, Jia-Ni
Wang, Rong
Li, Xiao-Lin
Ye, Wei-Wu
Ding, Xiao-Wen
Wang, Xiao-Jia
Cao, Wen-Ming
author_sort Zhu, Qiao-Yan
collection PubMed
description BACKGROUND: Four Fanconi anemia (FA) genes (BRCA1, BRCA2, PALB2 and RAD51C) are defined as breast cancer (BC) susceptibility genes. Other FA genes have been inconsistently associated with BC. Thus, the role of other FA genes in BC should be explored in specific populations. METHODS: Mutations in 16 FA genes were screened with a 98-gene panel sequencing assay in a cohort of 1481 Chinese patients with high-risk hereditary BC. The association between mutations and clinicopathological characteristics as well as prognosis was analyzed. The risk of BC in carriers of FA gene mutations was assessed in the Genome Aggregation Database and the Westlake Biobank for Chinese cohort. RESULTS: A total of 2.57% (38/1481) BC patients were identified who had 12 other FA gene germline mutations. Among them, the most frequently mutated gene was FANCA (8/1481, 0.54%). These 38 patients carried 35 distinct pathogenic/likely pathogenic variants, of which 21 were novel. We found one rare FANCB deleterious variant (c.1327-3dupT) in our cohort. There was a statistically significant difference in lymph node status between FA gene mutation carriers and non-carriers (p = 0.041). We observed a trend that mutation carriers had larger tumor sizes, lower estrogen receptor (ER) and progesterone receptor (PR) positivity rates, and lower 3.5-year invasive disease-free survival (iDFS) and distant recurrence-free survival (DRFS) rates than non-carriers (tumor size > 2 cm: 51.43% vs. 45.63%; ER positivity rates: 51.43% vs. 60.81%; PR positivity rates: 48.57% vs. 55.16%; 3.5-year iDFS rates: 58.8% vs. 66.7%; 3.5-year DRFS rates: 58.8% vs. 68.8%). The frequency of the mutations in FANCD2, FANCM and BRIP1 trended to be higher among BC cases than that in controls (p = 0.055, 0.08 and 0.08, respectively). CONCLUSION: This study comprehensively estimated the prevalence, clinicopathological characteristics, prognosis and risk of BC associated with deleterious variants in FA genes in Chinese high-risk hereditary BC patients. It enriches our understanding of the role of FA genes with BC.
format Online
Article
Text
id pubmed-10590287
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-105902872023-10-23 A comprehensive analysis of Fanconi anemia genes in Chinese patients with high-risk hereditary breast cancer Zhu, Qiao-Yan Li, Pu-Chun Zhu, Yi-Fan Pan, Jia-Ni Wang, Rong Li, Xiao-Lin Ye, Wei-Wu Ding, Xiao-Wen Wang, Xiao-Jia Cao, Wen-Ming J Cancer Res Clin Oncol Research BACKGROUND: Four Fanconi anemia (FA) genes (BRCA1, BRCA2, PALB2 and RAD51C) are defined as breast cancer (BC) susceptibility genes. Other FA genes have been inconsistently associated with BC. Thus, the role of other FA genes in BC should be explored in specific populations. METHODS: Mutations in 16 FA genes were screened with a 98-gene panel sequencing assay in a cohort of 1481 Chinese patients with high-risk hereditary BC. The association between mutations and clinicopathological characteristics as well as prognosis was analyzed. The risk of BC in carriers of FA gene mutations was assessed in the Genome Aggregation Database and the Westlake Biobank for Chinese cohort. RESULTS: A total of 2.57% (38/1481) BC patients were identified who had 12 other FA gene germline mutations. Among them, the most frequently mutated gene was FANCA (8/1481, 0.54%). These 38 patients carried 35 distinct pathogenic/likely pathogenic variants, of which 21 were novel. We found one rare FANCB deleterious variant (c.1327-3dupT) in our cohort. There was a statistically significant difference in lymph node status between FA gene mutation carriers and non-carriers (p = 0.041). We observed a trend that mutation carriers had larger tumor sizes, lower estrogen receptor (ER) and progesterone receptor (PR) positivity rates, and lower 3.5-year invasive disease-free survival (iDFS) and distant recurrence-free survival (DRFS) rates than non-carriers (tumor size > 2 cm: 51.43% vs. 45.63%; ER positivity rates: 51.43% vs. 60.81%; PR positivity rates: 48.57% vs. 55.16%; 3.5-year iDFS rates: 58.8% vs. 66.7%; 3.5-year DRFS rates: 58.8% vs. 68.8%). The frequency of the mutations in FANCD2, FANCM and BRIP1 trended to be higher among BC cases than that in controls (p = 0.055, 0.08 and 0.08, respectively). CONCLUSION: This study comprehensively estimated the prevalence, clinicopathological characteristics, prognosis and risk of BC associated with deleterious variants in FA genes in Chinese high-risk hereditary BC patients. It enriches our understanding of the role of FA genes with BC. Springer Berlin Heidelberg 2023-08-11 2023 /pmc/articles/PMC10590287/ /pubmed/37566130 http://dx.doi.org/10.1007/s00432-023-05236-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research
Zhu, Qiao-Yan
Li, Pu-Chun
Zhu, Yi-Fan
Pan, Jia-Ni
Wang, Rong
Li, Xiao-Lin
Ye, Wei-Wu
Ding, Xiao-Wen
Wang, Xiao-Jia
Cao, Wen-Ming
A comprehensive analysis of Fanconi anemia genes in Chinese patients with high-risk hereditary breast cancer
title A comprehensive analysis of Fanconi anemia genes in Chinese patients with high-risk hereditary breast cancer
title_full A comprehensive analysis of Fanconi anemia genes in Chinese patients with high-risk hereditary breast cancer
title_fullStr A comprehensive analysis of Fanconi anemia genes in Chinese patients with high-risk hereditary breast cancer
title_full_unstemmed A comprehensive analysis of Fanconi anemia genes in Chinese patients with high-risk hereditary breast cancer
title_short A comprehensive analysis of Fanconi anemia genes in Chinese patients with high-risk hereditary breast cancer
title_sort comprehensive analysis of fanconi anemia genes in chinese patients with high-risk hereditary breast cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590287/
https://www.ncbi.nlm.nih.gov/pubmed/37566130
http://dx.doi.org/10.1007/s00432-023-05236-6
work_keys_str_mv AT zhuqiaoyan acomprehensiveanalysisoffanconianemiagenesinchinesepatientswithhighriskhereditarybreastcancer
AT lipuchun acomprehensiveanalysisoffanconianemiagenesinchinesepatientswithhighriskhereditarybreastcancer
AT zhuyifan acomprehensiveanalysisoffanconianemiagenesinchinesepatientswithhighriskhereditarybreastcancer
AT panjiani acomprehensiveanalysisoffanconianemiagenesinchinesepatientswithhighriskhereditarybreastcancer
AT wangrong acomprehensiveanalysisoffanconianemiagenesinchinesepatientswithhighriskhereditarybreastcancer
AT lixiaolin acomprehensiveanalysisoffanconianemiagenesinchinesepatientswithhighriskhereditarybreastcancer
AT yeweiwu acomprehensiveanalysisoffanconianemiagenesinchinesepatientswithhighriskhereditarybreastcancer
AT dingxiaowen acomprehensiveanalysisoffanconianemiagenesinchinesepatientswithhighriskhereditarybreastcancer
AT wangxiaojia acomprehensiveanalysisoffanconianemiagenesinchinesepatientswithhighriskhereditarybreastcancer
AT caowenming acomprehensiveanalysisoffanconianemiagenesinchinesepatientswithhighriskhereditarybreastcancer
AT zhuqiaoyan comprehensiveanalysisoffanconianemiagenesinchinesepatientswithhighriskhereditarybreastcancer
AT lipuchun comprehensiveanalysisoffanconianemiagenesinchinesepatientswithhighriskhereditarybreastcancer
AT zhuyifan comprehensiveanalysisoffanconianemiagenesinchinesepatientswithhighriskhereditarybreastcancer
AT panjiani comprehensiveanalysisoffanconianemiagenesinchinesepatientswithhighriskhereditarybreastcancer
AT wangrong comprehensiveanalysisoffanconianemiagenesinchinesepatientswithhighriskhereditarybreastcancer
AT lixiaolin comprehensiveanalysisoffanconianemiagenesinchinesepatientswithhighriskhereditarybreastcancer
AT yeweiwu comprehensiveanalysisoffanconianemiagenesinchinesepatientswithhighriskhereditarybreastcancer
AT dingxiaowen comprehensiveanalysisoffanconianemiagenesinchinesepatientswithhighriskhereditarybreastcancer
AT wangxiaojia comprehensiveanalysisoffanconianemiagenesinchinesepatientswithhighriskhereditarybreastcancer
AT caowenming comprehensiveanalysisoffanconianemiagenesinchinesepatientswithhighriskhereditarybreastcancer